These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35280318)

  • 1. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
    Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
    Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
    BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of
    Zhao C; Jiang T; Li J; Wang Y; Su C; Chen X; Ren S; Li X; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1149-1158. PubMed ID: 32953493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT; Zhang SL; Han CB; Ma JT
    Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
    Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
    Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
    Grant MJ; Aredo JV; Starrett JH; Stockhammer P; van Alderwerelt van Rosenburgh IK; Wurtz A; Piper-Valillo AJ; Piotrowska Z; Falcon C; Yu HA; Aggarwal C; Scholes D; Patil T; Nguyen C; Phadke M; Li FY; Neal J; Lemmon MA; Walther Z; Politi K; Goldberg SB
    Clin Cancer Res; 2023 Jun; 29(11):2123-2130. PubMed ID: 36913537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports.
    Meng Y; Li X; Zhang L; Ye M
    Front Oncol; 2023; 13():1129629. PubMed ID: 37795433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.
    Gu Y; Yu J; Hu H; Zhang H; Cao B; Liang L
    Thorac Cancer; 2023 Nov; 14(31):3147-3160. PubMed ID: 37704565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
    Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
    J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
    Mehta A; Vasudevan S
    Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
    Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
    Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.
    Chung KP; Wu SG; Wu JY; Yang JC; Yu CJ; Wei PF; Shih JY; Yang PC
    Clin Cancer Res; 2012 Jun; 18(12):3470-7. PubMed ID: 22510346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
    Zhang Y; Wang Z; Hao X; Hu X; Wang H; Wang Y; Ying J
    Chin J Cancer Res; 2017 Feb; 29(1):18-24. PubMed ID: 28373750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
    World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.